Research programme: isocitrate dehydrogenase mutations companion diagnostic - Agios Pharmaceuticals/Foundation Medicine
Latest Information Update: 02 May 2019
At a glance
- Originator Agios Pharmaceuticals; Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 04 Apr 2013 Early research in Cancer (Diagnosis) in USA (unspecified route)